Career progression is rarely linear, and there is no single path to leadership. In our latest blog, Sinéad McKeon discusses what drove her move from the lab bench to project management. She reflects on the capabilities...
Filter blogs
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Mechanism of action in pediatric research
Discover how EMA’s proposed MoA-based PIP requirements mirror the US RACE for Children Act and how sponsors can prepare for pediatric regulatory changes.
-
Behind Biotech: Bojana Mirosavljevic
When companies seek support with rare disease patient advocacy, ICON Biotech’s Bojana Mirosavljevic brings hard won insights. As an embryologist and mother of a rare disease patient, she sees patient advocacy from the dual perspectives of science and caregiver.
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
The landscape of IPF research is evolving and early-stage biopharmaceutical teams need a new roadmap to success. We offer strategies to meet the challenges to develop new treatments.
-
Cross-border initiative to empower rare disease researchers
ICON joins new EU initiative to boost cross-border collaboration.
-
Beyond awareness: Driving progress on the Rare Disease journey
ICON employees share their experience with Rare Diseases.
-
Rare disease trials require effective participation support strategies to succeed
ICON is leading the way in rare disease clinical research having supported 778 rare disease clinical trials in the past five years. Every day, thousands of colleagues at ICON work tirelessly to support the success of rare disease clinical research – because patients can’t wait.
-
Strategies for de-risking rare disease programmes during research and development
Difficulties in research and development for rare disease therapeutics have been compounded by a historically challenging market for biotechs. ICON experts share how biotechs can maximise funding for rare disease therapeutic development in our blog.
-
Patient-centric best practices for improved diversity
In this blog, we share best practices for a more patient-centric approach to trials as discussed in our webinar to improve accessibility, inclusion and diversity.
-
Rare diseases and orphan drugs regulatory framework in Canada
This blog details initiatives that are being taken by the Government of Canada to promote a health care system that works for those with rare disorders.
-
Rare Disease Day diversity and inclusion
This event aims to raise awareness about the diversity of individuals affected by rare diseases. Find out how virtual events can be made more accessible and inclusive.
-
Filling the gaps for rare and orphan diseases
Read the blog to learn more about the benefits and challenges of Rare Disease natural history studies.
-
A rare partnership: collaborating with patient advocacy organisations for rare disease registries
Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups.
-
Clinical development challenges faced by advanced therapies for rare disease
Advanced therapies are a class of products based on genes, tissues or cells used to treat or deliver treatment to patients.
-
Advanced therapies for rare disease - a regulatory roadmap
Navigating advanced therapy development for rare diseases is challenging from many perspectives and requires a customised development strategy.
-
.png?crop=yes&w=210&h=209&itok=6eBv2e8J "Medical facility research environment")
Rare disease patients and advocates drive change in public policy
Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.
-
Sharing my rare disease story - Hayley Christensen
ICON's Hayley Christensen shares her personal experience with Cystic Fibrosis.
-
Sharing my rare disease story - Tamie Joeckel
ICON's Tamie Joeckel shares her personal experience with Type 3 Hereditary Angioedema.
-
Sharing my rare disease story - Amanda Huber
ICON's Amanda Huber shares her personal experience with Alpha-1 Antitrypsin Deficiency (Alpha-1).
-
Sharing my rare disease story - Julia Tonge
ICON's Julia Tonge shares her personal experience with Amniotic Band Syndrome (ABS).
-
Effective patient recruitment for rare disease research
With 350 million people affected worldwide, rare diseases represent a major unmet medical need. However, the timely recruitment of eligible participants is a challenge for any rare disease clinical trial.
